E

Elephas

Ex vivo oncology diagnostics for immunotherapy

Overview

Elephas develops a platform to predict how cancer patients will respond to immunotherapy. It runs ex vivo tests on fresh tumor biopsies, keeping the tissue alive and preserving the tumor microenvironment. The platform uses the Elephas Live Edge instrument to cut tissue precisely and a hydrogel called Live Protectâ„¢ to maintain viability. Treated samples are examined with multimodal microscopy and metabolic imaging to track immune activity, like T-cell activation and cancer cell killing, in real time. Results aiming to predict treatment efficacy appear within about 72 hours to help doctors choose or speed up effective therapies. The system is tumor-agnostic and serves two main groups: biopharma partners to accelerate drug development and clinicians for personalized treatment decisions.

Work here?Claim your company

About Elephas

Simplify's Rating
Not yet rated

We're working on gathering enough insights on this company, check back soon!

Industries

Data & AnalyticsEnterprise SoftwareBiotechnologyHealthcare

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$163.5M

Headquarters

Garrett Park, MD

Founded

2020

Get referred to Elephas

See people who can refer or advise you

Funding

Total Funding

$163.5M

Above

Industry Average

Funded Over

5 Rounds

Late VC funding comparison data is currently unavailable. We're working to provide this information soon!
Late VC Funding Comparison Coming Soon

Benefits

  • Health Insurance
  • Life Insurance
  • Flexible Spending Accounts
  • 401(k) Retirement Plan
  • Stock Options
  • Paid Vacation

Growth & Insights

6 month growth

8%

1 year growth

17%

2 year growth

37%

Recently Posted Jobs

Sign up to get curated job recommendations

Elephas is Hiring for 3 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs